Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2302684 | 0.85 | DYRK1A (0.54) | IMPDH2IMPDH1DYRK1ASLC6A4MAP2K1 | |
| SCHEMBL14722641 | 0.78 | IMPDH2 (0.47) | IMPDH2IMPDH1DYRK1ASLC6A4MAP2K1 | |
| SCHEMBL12361360 | 0.78 | SLC6A4 (0.48) | IMPDH2IMPDH1DYRK1ASLC6A4MAP2K1 | |
| SCHEMBL31663297 | 0.78 | SLC6A4 (0.48) | IMPDH2IMPDH1DYRK1ASLC6A4MAP2K1 | |
| SCHEMBL5256007 | 0.76 | DYRK1A (0.49) | IMPDH2IMPDH1DYRK1ASLC6A4MAP2K1 | |
| SCHEMBL28973447 | 0.76 | CYP2A6 (0.60) | SLC6A4CYP2A6CLK1CDK5CDK5R1 | |
| SCHEMBL24328229 | 0.74 | SLC6A4 (0.45) | IMPDH2IMPDH1DYRK1ASLC6A4MAP2K1 | |
| SCHEMBL11761255 | 0.74 | CYP2A6 (0.58) | IMPDH2IMPDH1SLC6A4MAP2K1CYP2A6 | |
| SCHEMBL29953438 | 0.74 | CYP2A6 (0.58) | IMPDH2IMPDH1SLC6A4MAP2K1CYP2A6 | |
| SCHEMBL2430350 | 0.71 | AR (0.37) | IMPDH2IMPDH1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805664-B | Bionic modified marine antifouling resin material, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-114805664-A | Bionic modified marine antifouling resin material, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-114292582-B | Hyperbranched coating suitable for marine concrete, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-114292582-A | Hyperbranched coating suitable for marine concrete, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2022-04-08 | — | — | CN | claimed |
| EP-4536668-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-119630676-A | Pyrido [4,3-D ] pyrimidine derivatives as KRAS inhibitors | 百时美施贵宝公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20240067662-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-02-29 | — | — | US | disclosed |
| US-20240067662-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-02-29 | — | — | US | disclosed |
| US-20240067662-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-02-29 | — | — | US | disclosed |
| WO-2023240188-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023240188-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-114805664-B | Bionic modified marine antifouling resin material, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2023-04-14 | — | — | CN | disclosed |
| WO-2022061251-A1 | COMPOUNDS AND METHODS FOR KRAS MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2022-03-24 | — | — | WO | disclosed |
| US-RE45173-E1 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20140228394-A1 | INHIBITORS OF CYP 17 | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| CN-102803250-B | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP17 | NOVARTIS AG | 2014-04-16 | — | — | CN | disclosed |
| EP-2445903-B1 | 1,3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF CYP 17 | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| CN-102803250-A | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP17 | NOVARTIS AG | 2012-11-28 | — | — | CN | disclosed |
| US-8263635-B2 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20100331326-A1 | Inhibitors of CYP 17 | NOVARTIS AG | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331326-A1 | Inhibitors of CYP 17 | CYP17A1, CYP21A2, CYP4A22 | IMPDH2 288/4885IMPDH1 228/4885DYRK1A 3893/4885 |
| US-20140228394-A1 | INHIBITORS OF CYP 17 | CYP17A1, CYP21A2, CYP4A22 | IMPDH2 288/4885IMPDH1 228/4885DYRK1A 3893/4885 |
| US-20240067662-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | IMPDH2 3239/4885IMPDH1 3174/4885DYRK1A 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.